← REGULATORY CHANGES
FEDERAL REGISTER · PROPOSED RULESeptember 22, 2026PROPOSED — NOT IN FORCEOPEN FOR COMMENT

Nonclinical Testing Terminology

What this record is not

Document details are published in the U.S. Federal Register; SPEQ surfaces them for reference and is not affiliated with or endorsed by the FDA or the Office of the Federal Register. The authoritative text is on federalregister.gov.

STATUSPROPOSED — NOT IN FORCE
PROPOSED EFFECTIVE—
COMMENTS CLOSEDec 7, 2026 · in 41 days
APPLIES TO · SPEQ TAGDrugDevice
Document type
Proposed Rule
Agency
Health and Human Services Department
Published
September 22, 2026
Comments close
December 7, 2026
Document number
2026-19349
CFR references
21 CFR 312, 21 CFR 314, 21 CFR 315, 21 CFR 361, 21 CFR 601
Docket
FDA-2026-N-5347
RIN
0910-AJ27
ABSTRACT

The Food and Drug Administration (FDA, Agency, or we) is proposing to substitute references to "animal" tests or studies with "nonclinical" tests or studies, add a definition of the terms "nonclinical test" and "nonclinical study," and make other comparable or conforming amendments in certain safety and reporting sections of its regulations. The proposed rule would also substitute "nonclinical" for "preclinical" and "in vitro" for consistency in terminology. These proposed amendments align with recent amendments to the Federal Food, Drug, and Cosmetic Act (FD&C Act) and the Public Health Service Act (PHS Act) and are intended to remove an emphasis, in certain places, on the use of animal testing as the only scientific methodology to assess the safety of a drug in the nonclinical setting. These changes may also foster the development and use of scientifically valid new testing methodologies, potentially improving predictive accuracy of product safety testing while replacing, reducing, or refining animal use. The proposed rule would add no new requirements.

Abstract as published in the Federal Register.

The comment window is still open until December 7, 2026. This is a proposal, and the comment window is the point at which the text is still negotiable — industry input here shapes what the final rule says. Submit comments through the Federal Register document below.

READ THE FULL DOCUMENT

The complete document — every provision, the docket, and the comment instructions — is published in the Federal Register. SPEQ surfaces and indexes it for reference; the authoritative text lives on federalregister.gov.

View on federalregister.gov →

That is what FDA published. A free account files it on your watchlist and sends one weekly email with whatever lands next.

Create a free account